All PlansAdministrativeMedium impact
MA08.142f, Efgartigimod alfa-fcab (Vyvgart) and efgartigimod-alfa and hyaluronidase-qvfc (Vyvgart Hytrulo)
Independence Blue Cross·Medical Policy
We identified it
Jul 28, 2026
Summary
Failed to analyze policy change